SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Lupin Ltd

BSE: 500257 NSE: LUPIN ISIN: INE326A01037
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Lupin Ltd belong to?
Lupin Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Lupin Ltd a good quality company?
Lupin Ltd is a average quality company, based on a somewhat consistent 10 year financial track record.
Q.3 Is Lupin Ltd undervalued or overvalued?
Lupin Ltd appears Somewhat overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is Lupin Ltd a good buy now?
Lupin Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Lupin Ltd?
Lupin Ltd revenue growth is 13.5% for FY-2025 , which is above its 5 year CAGR of 8.1% , indicating faster growth.
Q.2 Gross Profit margin of Lupin Ltd?
Lupin Ltd Gross profit margin which is the profit after deduction of direct costs, is 13.9% for FY-2025 , which is above its 5 year median of 9.1% , indicating increasing margins.
Q.3 Operating Profit Margin of Lupin Ltd?
Lupin Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 23.26% for FY-2025 , which is above its 5 year median of 17.53% indicating increasing margins.
Q.4 Net Profit Margin of Lupin Ltd?
Lupin Ltd Net Profit Margin is 14.56% for FY-2025 , is above with its 5 year median of 8.1%, indicating increasing margins.
Current Level Historic Median
Gross Profit Margin 13.9 9.1
Operating Profit Margin 23.26 17.53
Net Profit Margin 14.56 8.1
Q.5 Return on Asset of Lupin Ltd?
Lupin Ltd Return on Asset is 12.63%, which is above its 5 year historical median of 5.09%, indicating improved asset utilization efficiency.
Q.6 Return on Equity (ROE) of Lupin Ltd?
Lupin Ltd Return on equity is 21.13% for FY-2025 , which is above its historical median of 9.47%, indicating the business is making better use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Lupin Ltd?
Lupin Ltd Return on capital employed is 21.97% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 11.25%, indicating value creation.
Q.8 Cash conversion cycle of Lupin Ltd?
Lupin Ltd Cash conversion cycle is 35 days, below its historical median of 50 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 1.42 1.32
ROE 21.13 9.47
ROCE 21.97 9.71
Cash Conversion Cycle 35 days 50 days
Q.9 Debt to Equity ratio of Lupin Ltd?
Lupin Ltd Debt-to-Equity ratio is 0.30 , which is above with the industry average of 0.13 , indicating higher debt levels in the industry.
Q.10 Debt to cash flow from operations of Lupin Ltd?
Lupin Ltd Debt to cash flow from operations is 1.69 , which is at a moderate level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Lupin Ltd?
Promoters hold 46.89% of the Lupin Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Lupin Ltd vs industry peers?
Lupin Ltd revenue CAGR is 8.11% , compared to the industry median CAGR of 8.87% , indicating slower growth and losing its market share.
Profit Metrics
Current Level Industry Median
Revenue 22,707.9 8,127.2
Gross Profit 3,156.4 1,337.7
Operating Profit 5,278 1,810
Net Profit 3,306 970
Operating Efficiency
Current Level Industry Median
Asset Turnover 1.42 0.8
ROE 21.13 18.61
ROCE 21.97 17.96
Cash Conversion Cycle (days) 34.59 76

Valuation & price assessment

Q.1 Stock return of Lupin Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 4% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price 4% 16.2% 49.3% 15.1%
Q.3 Valuation ratios of Lupin Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 22.92 0.00 40.28
Price to Book 5.12 3.45 2.77
Price to Sales 4.15 2.90 2.65
EV to EBITDA 13.66 18.27 15.67

Check more companies

1. Lupin
2. Dr. Reddys Lab
3. Zydus Lifesciences
4. Mankind Pharma
5. Aurobindo Pharma
6. Alkem Laboratories
7. Glenmark Pharma
8. Laurus Labs
9. Biocon
10. Abbott India
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×